Expired activity
Please go to the PowerPak homepage and select a course.

Multidrug Resistant Bacteria – An Ongoing Global Healthcare Challenge

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and supported by an educational grant from Merck & Company.

Release Date: June 30, 2016
Expiration Date: June 30, 2017


James Lewis, PharmD (Faculty)
Clinical Pharmacist
Antimicrobial Management Team
Department of Pharmacy Services
Oregon Health & Science University
Portland, OR

Carlene A. Muto, MD, MS (Faculty)
Associate Professor of Medicine
Medical Director of Infection Control
Center for Quality Improvement and Innovation
UPMC Health System
Pittsburgh, PA

Marlene Hilton (Moderator)


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

Disclosures of the following financial relationships have been provided:

James Lewis, PharmD
Consultant: Astellas, Accelerate Diagnostics, Achaogen, Merck & Company, The Medicines Company, Allergan

Carlene A. Muto, MD, MS
Nothing to disclose

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.


The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

This activity has been approved for 1 contact hour.

ACPE Universal Activity Number: 0396-0000-16-047-H01-P
Activity Type(s): Knowledge

Fee Information: There is no fee for this educational activity

Estimated time to complete activity: 60 minutes


This activity is intended to educate physicians, nurses, pharmacists, and other clinicians involved in the treatment of multidrug resistant infections.


This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 70% must be achieved on the post-test. A statement of participation will be immediately available. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days. For questions about this activity, please contact Michelle Forcier at mforcier@achlcme.org.


Multidrug resistant bacteria represent an ongoing global healthcare challenge, with changing epidemiology and resistance patterns resulting in increased morbidity and mortality rates among hospitalized patents. This activity will review the impact of extended-spectrum beta-lactamase and carbapenemase-producing bacteria and present comparative data on current and emerging therapies to develop strategies for initial therapy and optimal outcomes.


Upon completion of this activity, participants will be better able to:

  1. Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens
  2. Summarize the salient features and critical differences amongst available antibiotics and those in development for use against multidrug resistant gram-negative bacteria
  3. Describe strategies to optimize initial antimicrobial therapy to ensure effectiveness of antibiotics and reduce the development of resistance
  4. Discuss the interventions with the potential to reduce inappropriate use of antibiotics and improve outcomes in patients with resistant bacterial infections


This site is best viewed with an HTML5 compatible browser; this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentations, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use and Disclaimer

The faculty in this activity may discuss investigational uses of novel therapies under investigation for multidrug resistant bacterial infections. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.